MYLK Antibody (MLJ-9): sc-69868

MYLK Antibody (MLJ-9) is a mouse monoclonal IgG1 antibody that detects myosin light chain kinase (MYLK) in human samples through western blotting (WB). MYLK is a crucial enzyme that plays a significant role in muscle contraction by phosphorylating myosin regulatory light chains, which facilitates the interaction between myosin and actin filaments, ultimately leading to contractile activity. This process is vital not only in muscle tissues but also in various non-muscle cells, where MYLK isoforms contribute to cellular functions such as motility and shape maintenance. The MYLK gene encodes multiple isoforms, including those specific to smooth muscle and non-muscle tissues, as well as telokin, a unique isoform that stabilizes unphosphorylated myosin filaments in smooth muscle. The presence of different MYLK isoforms across a wide range of adult and fetal tissues underscores MYLK′s importance in diverse physiological processes. MYLK interacts with p21-activated kinases (PAKs), which can modulate MYLK activity; for instance, the interaction with PAK1 leads to a decrease in MYLK activity and subsequent myosin light chain phosphorylation, highlighting the regulatory mechanisms that control muscle contraction and cellular dynamics.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MYLK Antibody (MLJ-9) References:

1. MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance epithelial-mesenchymal transition.  |  Lin, J., et al. 2018. Clin Exp Med. 18: 523-533. PMID: 29855744
2. MYLK pathogenic variants aortic disease presentation, pregnancy risk, and characterization of pathogenic missense variants.  |  Wallace, SE., et al. 2019. Genet Med. 21: 144-151. PMID: 29925964
3. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652.  |  Zhao, Y., et al. 2020. Eur Rev Med Pharmacol Sci. 24: 5281-5291. PMID: 32495861
4. Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2.  |  Zhu, S., et al. 2021. J Cell Physiol. 236: 5757-5770. PMID: 33438217
5. LncRNA MYLK-AS1 acts as an oncogene by epigenetically silencing large tumor suppressor 2 (LATS2) in gastric cancer.  |  Luo, J. and Xiang, H. 2021. Bioengineered. 12: 3101-3112. PMID: 34181498
6. miR-181a-2-3p Stimulates Gastric Cancer Progression via Targeting MYLK.  |  Li, J., et al. 2021. Front Bioeng Biotechnol. 9: 687915. PMID: 34733825
7. Circular RNA MYLK as a prognostic biomarker in patients with cancers: A systematic review and meta-analysis.  |  Foroumadi, R., et al. 2022. Cancer Rep (Hoboken). 5: e1653. PMID: 35701309
8. MYLK and CALD1 as molecular targets in bladder cancer.  |  Jin, H., et al. 2023. Medicine (Baltimore). 102: e36302. PMID: 38013282
9. The SNHG12/microRNA-15b-5p/MYLK axis regulates vascular smooth muscle cell phenotype to affect intracranial aneurysm formation.  |  Feng, W., et al. 2024. Microvasc Res. 152: 104643. PMID: 38081409
10. Aging aggravates aortic aneurysm and dissection via miR-1204-MYLK signaling axis in mice.  |  Liu, ZL., et al. 2024. Nat Commun. 15: 5985. PMID: 39013850

The preferred MYLK antibody is MYLK Antibody (A-8): sc-365352.